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Congestive heart failure is a progressive disorder in which
the hemodynamic and symptomatic status of affected pa-
tients deteriorates over a period of months to years, even in
the absence of clinically apparent intercurrent events
. De-
spite extensive characterization of the biochemical and
physiologic abnormalities in this disease, the cause of this
progressive decline in ventricular performance remains un-
known . Some observers have suggested that myocardial
function deteriorates in chronic heart failure as a conse-
gttence of the cumulative damage that might be expected to
follow any prolonged hemodynamic stress . According to this
concept, any increase in left ventricular dimensions and wall
stress leads to excessive energy utilization by the failing
heart, which in turn leads (in some fashion) to a loss of viable
myocardium . Although attractive, this hypothesis remains
speculative ; the lack of supporting evidence suggests that
alternative possibilities should be explored . In this regard it
is noteworthy that the neurohormonal systems that are
activated in chronic heart failure have physiologic actions
that are deleterious to myocardial function ; such activation
offers an appealing explanation for the progressive deterio-
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Figure 1 . Relation between left ventricular ejection
fraction and plasma norepinephrine in patients with
chronic congestive heart failure . Reproduced, by per-
mission, from Maurer et at . (7) .
ration seen in patients with advanced left ventricular dys-
function. It is my intent in this review to present arguments
supporting the concept that neurohormonal stimulation ac-
celerates the rate of progression of cardiac dysfunction and
is deleterious to the long-term survival of patients with
chronic heart failure .
Although numerous studies (1) have shown that left
ventricular function is a powerful predictor of survival in
heart failure, it is possible that this association exists be-
cause left ventricular dysfunction is a marker for heightened
neurohormonal activity (2) ; if so, it is likely that this neuro-
hormonal stimulation (rather than hemodynamic factors) has
direct pathogenetic significance with respect to survival. A
number of neurohormonat systems are activated as left
ventricular function declines, but this review will focus only
on the two primary vasoconstrictor systems : the sympa-
thetic nervous system and the renin-angiotensin system.
Sympathetic Nervous System
The sympathetic nervous system is activated in patients
with congestive heart failure, as determined by intraneuml
recordings of peripheral nerve activity and by the measure-
ment of circulating catecholamines (2,3) . Despite the marked
increase in sympathetic nerve traffic to the ventricle, myo-
cardial levels of norepinephrine are generally depleted in this
disorder (4). This depletion may occur either because of a
defect in catecholamine synthesis (5) or because of enhanced
release of norepinephrine from the failing heart (perhaps
related to a defect in neurotransmitter binding) (6) . The
degree of activation of the sympathetic nervous system in
chronic heart failure varies greatly among affected patients,
but the intensity of the neurohormonal reaction seems to be
proportional to the severity of the hemodynamic abnormal-
ities in this disease
. Such neurohormonal activation becomes
swenuenu
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particularly apparent when the left ventricular ejection frac-
tion decreases to <40% (Fig . 1) (7) .
Is activation of the sympathetic nervous system beneficial
or detrimental to patients with chronic heart failure? Al-
though the increase in sympathetic nerve traffic might act to
support the contractile function of the failing myocardium,
such support does not appear to be required to maintain
circulatory homeostasis because sympathetic inhibition does
not predictably result in worsening heart failure . It seems
more likely that activation of the sympathetic nervous sys-
tem exerts a deleterious effect in this syndrome . Several
studies (8,9) have demonstrated that high concentrations of
catecholamines can cause myocardial necrosis, both in ex-
perimental models and in the clinical setting
. Although the
concentration of catecholamines required to produce such
toxicity is greater than that found in the plasma of most
patients with heart failure, it is likely that the concentration
of norepinephrine surrounding the myocardial cell is sub-
stantially higher than the levels that can be measured in the
peripheral circulation (10,11) . Catechalamines act to in-
crease the level of cyclic adenosine menophosphate (AMP)
in the myocardial cell; this nucleotide can exacerbate
arrhythmias and enhance cell necrosis by virtue of its ability
to increase cytosolic calcium . These adverse physiologic
actions, if exerted for prolonged periods, might accelerate
the rate of disease progression and increase the risk of death
in chronic heart failure .
Plasma catecholamtnene level as a predictor of mortality .
The detrimental effects of prolonged sympathetic activity
may explain why the measurement of plasmanorepinephrine
is a powerful predictor of the long-term mortality of patients
with chronic heart failure ; plasma catecholamines appear to
be a better predictor of survival than are conventional
hemodynamic variables or other measures of ventricular
performance
(12) .
Patients with heart failure with a plasma
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norepinephrine level >800 pglml have a I year mortality rate
of 73%, but this mortality rate declines to only 27% when the
circulating level of norepinephrine is <400 pg/ml .
If the sympathetic nervous system were deleterious to
patients with chronic heart failure, we might expect the
myocardium to develop means of protecting itself against the
adverse biochemical effects of prolonged activation . Data
from the laboratory of Bristow and coworkers (10,11) sug-
gest that this may occur in both experimental and clinical
heart failure . Myocardial beta-adrenergic receptors undergo
a process of "down-regulation" in response to the height-
ened sympathetic activity ; the density of beta-receptors
decreases in proportion to the level of catecholamines mea-
sured in the coronary sinus (II) . This loss of functional
receptors is accompanied by a decrease in the ability of the
myocardium to respond (in either a beneficial or a deleteri-
ous fashion) to beta-agonist activity .
Effect of adrenergic blockade on long-term outcome. By
blocking these adverse effects of prolonged sympathetic
stimulation, beta-adrenergic blocking drugs appear to reduce
the high mortality of patients with chronic heart failure
(13,14). This benefit appears to be related to interference
with the action of the sympathetic nervous system on the
myocardium because therapeutic attempts to block the pe-
ripheral vascular actions of the sympathetic nervous system
(with the alpha,-adrenergic antagonist, prazosin) do not
appear to prolong life in this disorder (15) .
Beta-adrenergic blockade reduces the mortality of pa-
tients with ischemic heart disease who have survived the
early phase of an acute myocardial infarction (16-18). The
most marked benefits from this treatment have generally
been observed in patients with the largest index infarction,
who presumably are at greatest risk of developing congestive
heart failure in the subsequent months and years . Beta-
blockade reduced mortality in these high risk patients from
approximately 16% to only 10% in the Beta-Blocker Heart
Attack Trial (16),
the Norwegian Multicenter Timolol Study
(17) and in our own Gothenburg Metoprolol Trial (18) .
A similar beneficial effect of long-term beta-blockade has
been reported inpatients without ischemic heart disease who
manifest signs and symptoms of congestive heart failure
secondary to an idiopathic dilated cardiomyopathy . Data
from our laboratory (19,20) over the past 10 years have
consistently shown that sustained treatment with metoprolol
produces hemedynamic and clinical improvement in these
patients
; such benefits rapidly disappeared after the with-
drawal of therapy (21). In our group, Finn Waagstein re-
cently evaluated 26 patients with a dilated cardiomyopathy
who were treated with metoprotol for ?6 months (mean I I
months). The New York Heart Association functional class
of these patients improved from 3.3 to 1 .9 as the left
ventricular ejection fraction increased from 0 .24 to 0.42 .
Further studies in these patients suggested that this improve-
ment in systolic performance was also accompanied by an
JACC Vol
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improvement in diastolic function . Our work was recently
confirmed by investigators in the United States (22,23) in
controlled clinical trials with metoprolol and bucindolol .
Finally, in a nonrandomized analysis of survival that we
carried out using historical controls, beta-blockade appeared
to prolong life in patients with a dilated cardiomyopathy (13) .
This encouraging result awaits direct confirmation in a
prospective, randomized, controlled clinical trial. Such a
study (Metoprolol in Dilated Cardiomyopathy) is now
being conducted in centers in Europe and the United
States.
Renin-Angiotensin System
The renin-angiotensin systern is activated in patients with
congestive heart failure, as reflected by an increase in
plasma renin activity and by the circulatory response to the
suppression of angiotensin II formation
. The degree of this
activation varies with the severity of the heart failure state,
assessed either symptomatically or hemodynamically; the
most marked activation is seen in patients with hyponatre-
mia, who have the most compromised renal blood flow
(24,25).
Is activation of the renin-angioteasin system beneficial or
detrimental in chronic heart failure? Although the formation
of angiotensin 11 might be expected to support systemic
perfusion and glomerular filtration pressures, prolonged ac-
tivation of this system seems to be accompanied by specific
detrimental hemodynamic and biochemical consequences.
Angiotensin is a potent systemic vasoconstrictor and poten-
tiates the activity as well as the actions of other vasocon-
strictor systems (for example, the sympathetic nervous
system and vasopressin) . Angiotensin also stimulates the
release of aldosterone and thereby causes sodium and water
retention . Acting in concert, these two primary physiologic
effects of angiotensin markedly increase loading conditions
in the failing heart and may accelerate progression of the
underlying cardiac disorder.
This sequence of events has now been demonstrated in an
experimental model of congestive heart failure induced in
dogs by rapid ventricular pacing (26) . Such rapid pacing
induced a state similar to congestive heart failure within 7
days . Cardiac output declined, systemic vascular resistance
increased and signs of heart failure (fluid retention and
pleural effusions) became apparent
; these hemodynamic
changes were accompanied by activation of the renin-
angiotensin system . In contrast, when a similar pacing
protocol was utilized in dogs treated with the converting
enzyme inhibitor captopril, systemic vascular resistance did
not increase and clinical heart failure did not develop ; these
benefits were associated with biochemical evidence of inter-
ference with the renin-angiotensin system .
These deleterious circulatory effects of angiotensin Ii
may explain why variables that reflect the activity of the
JACC VA 12, No .2
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FIgure 2, Cumulative probability of death n
in patients with severe chronic heart failure
assigned to placebo or enalapril in the CON-
SENSUS stud
Reproduce by permit-
.
,
03
sion, from the CONSENSUS Trial Study -
Group (30).
0.2.
Plorebw N 126
	
112 76
rmbp,i4N-.127 111 a6
SWEOBERG 553
PROTAGONISTS VIEWPOINT
. .
.
... . .... .
EOMawa-
3
4 5
6
7 6 9 Rr 11 12
onth.
67 58 53
M
47 42 34 ao 24 IS 17
66 82 79 72 54 54 48 42 31 26
0 1 2
due to interference with the lethal effects of the renin-
ungiotensin system? A preliminary (but as yet unpublished)
analysis of the neurohormonal-mortality interactions in this
study appears to confirm this hypothesis . Mortality rates in
the CONSENSUS trial were directly related to the pretreat-
ment plasma concentrations of angiotensin II and aldoste-
rone in patients randomized to placebo, the highest mortality
being seen in patients with the highest circulating level of
tnis hormone
. A similar relation between plasma angiotensin
11 or aldosterone and survival was not apparent, however, in
patients treated with enalapril, largely because treatment
with the converting enzyme inhibitor reduced mortality in
patients with high plasma levels of these hormones but not in
patients who showed minimal acti-ation of the renin-
angiotensin system
. These data strongly suggest that the
benefits of converting enzyme inhibition on the survival of
patients with chronic heart failure are related to interference
with the renin-angiotensin system and cannot
be explained
by a nonspecific peripheral vasodilator effect
. A similar
relation between the activity of the renin-angiotensin system
and the magnitude of mortality reduction achieved by con-
verting enzyme inhibition in chronic heart failure has been
noted by other investigators (27)
.
Conclusions. There is overwhelming evidence that neu-
rohormonal activation adversely affects both myocardial and
circulatory function in patients with chronic congestive heart
failure. This concept seems to explain why neurohormonal
measurements provide important and independent prognos-
tic information in these patients and why treatment with
drugs that interfere with neurohormonal activity can prolong
life in this disease .
renin-angiotensin system have prognostic significance in
patients with congestive heart failure. Patients with the
greatest neurohormonal activation (assessed either by the
measurement of high levels of active renin or by the mea-
surement of a low serum sodium concentration) have the
least favorable long-term outcome (27,28) . The degree of
activation of the renin-angiotensin system is a more powerful
predictor of long-term outcome than are conventional hemo-
dynamic variables .
If the renin-angiotensin system were detrimental to pa-
tients with chronic heart failure, we might expect the circu-
lation to develop a means of defending itself against such
heightened neurohormonal activity. Modulation of the ac-
tions of the renin-angiotensin system may be achieved by the
release of atrial natriuretic peptide . This factor may limit the
release of renin as well as the actions of angiolensin II and,
thus may act as an effective counterregulatory hormone in
this disorder (29).
Effect of angiotensin inhibition on long-term outcome . The
Cooperative North Scandinavian Enalapril Survival Study
(CONSENSUS) (30) provides compelling evidence that the
renin-angiotensin system exerts a deleterious effect on the
survival of patients with heart failure . In this study, 253 men
and women with class IV heart failure were randomly
assigned to treatment with either placebo or the converting
enzyme inhibitor enalapril, in addition to conventional ther-
apy with digitalis, diuretics and direct-acting vasodilators .
Enalapril reduced mortality in these patients by 40% after 6
months and by 31% after I year of follow-up (Fig. 2) . Most
of this beneficial effect appeared in he explained by a 50%
reduction in death due to progressive heart failure .
Was the reduction in mortality in the CONSENSUS
trial
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Considerable evidence has accumulated during the past
decad : that c.'rfirms the hypothesis that peripheral arterial
and venous constriction may adversely affect the perform-
ance of the failing heart by increasing ventricular preload
and afterload.
(1) . Several laboraaries (2-4) have also
shown that patients with heart failure have activation of
neurohormonal systems (as evidenced by high plasma levels
of nnrepinephrine, renin activity and vasopressin) that may
contribute to systemic vasoconstriction . These observations
have led to the hypothesis that neurohormonal activation is
